Israel Ischemic Heart Disease (IHD) Drugs Market is expected to be dominated by Therapeutic Class type through 2028
Israel Ischemic Heart Disease (IHD)
Drugs Market is expected to be dominated
by Therapeutic Class type through 2028
Rising incidence of cardiovascular
diseases is expected to drive the growth of the Israel ischemic heart disease (IHD)
drugs market during the forecast period, 2018-2028, According to TechSci Research report, “Israel
Ischemic Heart Disease (IHD) Drugs Market - By Region, Forecast and
Opportunities, 2018-2028”,
the Israel
ischemic heart disease (IHD) drugs market is expected to grow with an
impressive CAGR during the forecast period 2018-2028. The rise in prevalence of
chronic diseases and growing awareness among key market players, including
manufacturers, who are involved in new drug production with high efficacy,
acquisitions, expansions, and strategic collaborations, and recent developments
show the growth of the ischemic heart disease (IHD) drugs market.
However, one of the main
contributing factors to the increasing prevalence of ischemic heart diseases is
the aging population. As people age, the risk of developing hypertension
increases. In addition, rising consumer awareness regarding the benefits of
scheduled administration of these drugs is driving the growth of the Israel
ischemic heart disease (IHD) drugs market during the forecast period.
Additionally, lifestyle
habits such as excessive alcohol consumption and smoking along with physical
inactiveness are leading to the growth of the Israel ischemic heart disease (IHD)
drugs market.
Browse over 30 market data Figures
spread through 70
Pages and an in-depth TOC on "Israel Ischemic Heart Disease (IHD)Drugs Market"
The Israel ischemic heart disease (IHD) drugs
market can be segmented by disease class, drug class, distribution
channel, and region.
The Israel ischemic heart
disease (IHD) drugs market can be segmented by disease class, drug class, and region. Based on disease class, the
market can be segmented into angina pectoris and myocardial infarction. Based on
disease class, the market can be bifurcated into angina pectoris and myocardial
infarction. The angina pectoris segment occupied the largest ischemic heart
disease drugs market share in 2018, as they are easily treatable by lifestyle
changes. However, the myocardial infarction segment is anticipated to depict
fastest growth during the forecast period.
Based on the drug class, the market can
be classified into following categories, anti-dyslipidemic drugs, calcium
channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic
agents. The calcium channel blockers segment is expected to show an impressive
growth during the forecast period due to new technology that lowers blood
pressure with less side effects.
Major companies operating in the Israel ischemic
heart disease (IHD) drugs market include:
- Pfizer Pharmaceuticals Israel Ltd
- MERCK SERONO LTD.
- GlaxoSmithKline Israel Ltd
- Bayer-Israel
- Novartis Pharma Israel Ltd
- Sanofi-Aventis Israel Ltd
- Eli Lilly Israel
- Actelion Pharmaceuticals Israel Ltd
- Bristol-Myers Squibb Israel Ltd.
- Roche Pharmaceuticals (Israel) Ltd
Download Free Sample Report
Customers can also request for 10% free customization on this
report.
“The Israel ischemic heart disease (IHD) drugs market is expected to
witness significant growth during the forecast period on account of growing
number of research and development in ischemic heart diseases. The
technological advancement supports the demand for ischemic heart disease (IHD) in
Israel. Additionally, an increase in emergence of players developing new drugs
to prevent from heart failure and heart stroke, is expected to create lucrative
opportunities for the market growth in the next few years” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based global
management consulting firm.
“Israel Ischemic
Heart Disease (IHD) Drugs Market, Disease Class (Angina Pectoris, Myocardial
Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers,
Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By
Region, Competition Forecast & Opportunities, 2028”, has evaluated the
future growth potential of the Israel Ischemic Heart Disease (IHD) Drugs Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the Israel ischemic heart disease (IHD) drugs
market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com